Cosupplementation with DHA and medium‐chain triglycerides ameliorates NAFLD and reduces amyloid‐β accumulation by modulating hepatic lipid metabolism in APP/PS1 mice

• Published in: Lipids Vol. 60; no. 4; pp. 211 - 227
• Main Authors: Zhang, Dalong, Wang, Zehao, Wang, Xiaojun, Yue, Wenbo, Zhang, Lu, Gao, Zheng, Li, Min, Zhou, Xiaoli, Li, Zhenshu, Huang, Guowei, Li, Wen, Zhou, Dianming, Qian, Zhiyong
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.07.2025
• Subjects: Alzheimer Disease - metabolism; Amyloid beta-Peptides - metabolism; Amyloid beta-Protein Precursor - genetics; Amyloid beta-Protein Precursor - metabolism; amyloid‐β clearance; Animals; Dietary Supplements; Disease Models, Animal; docosahexaenoic acid; Docosahexaenoic Acids - administration & dosage; Docosahexaenoic Acids - pharmacology; lipid metabolism; Lipid Metabolism - drug effects; Liver - drug effects; Liver - metabolism; Male; medium‐chain triglycerides; Mice; Mice, Inbred C57BL; Mice, Transgenic; NAFLD; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - pathology; Triglycerides - administration & dosage; Triglycerides - pharmacology; medium‐chain triglycerides; NAFLD; amyloid‐β clearance; docosahexaenoic acid; lipid metabolism

Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases and is associated with Alzheimer's disease (AD). Both docosahexaenoic acid (DHA) and medium chain triglycerides (MCTs) play essential roles in lipid metabolism and the inhibition of amyloid‐β (Aβ) accumula...